Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing just fine, thank you, now that the official mascot has settled into his designated snoozing corner and the short person is hovering over a laptop for another round of remote learning, such as it is. As for us, we are engaged in our usual ritual of brewing cups of stimulation — today, our choice is glazed doughnut — and foraging for items of interest. On that note, here are some tidbits. We hope your day is calm, safe, and productive. Meanwhile, do stay in touch, and stay safe — wear a mask. …

Gilead Sciences (GILD) is testing remdesivir to determine whether the drug is effective in treating new Covid-19 strains that emerged in the U.K. and South Africa, CNBC says. The antiviral drug, which last fall became the first treatment approved for Covid-19 in the U.S., has helped shorten the recovery time for some patients who are hospitalized with the coronavirus. Meanwhile, even with sales of the medicine surging, investors are not impressed, STAT notes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.